6,228 Amgen Inc. $AMGN Shares Sold by Avity Investment Management Inc.

Avity Investment Management Inc. decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 8.2% in the third quarter, Holdings Channel.com reports. The firm owned 69,958 shares of the medical research company’s stock after selling 6,228 shares during the period. Amgen makes up approximately 1.8% of Avity Investment Management Inc.’s investment portfolio, making the stock its 26th biggest position. Avity Investment Management Inc.’s holdings in Amgen were worth $29,488,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. State Street Corp lifted its stake in Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Amgen during the second quarter valued at about $1,831,903,000. Wellington Management Group LLP boosted its holdings in Amgen by 1,102.7% during the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after acquiring an additional 2,514,254 shares during the period. BlackRock Inc. grew its position in Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after acquiring an additional 2,261,544 shares during the last quarter. Finally, Corient Private Wealth LP bought a new position in Amgen during the 2nd quarter worth approximately $187,401,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last quarter. Company insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Cantor Fitzgerald boosted their price objective on Amgen from $400.00 to $440.00 and gave the company a “neutral” rating in a research report on Monday. Barclays raised their target price on shares of Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. UBS Group lifted their target price on shares of Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research note on Friday. Morgan Stanley dropped their price target on shares of Amgen from $362.00 to $359.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, HSBC cut Amgen from a “buy” rating to a “hold” rating and cut their target price for the stock from $445.00 to $425.00 in a research note on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $389.71.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: UBS upgraded Amgen to Buy and raised its price target to $470 from $430, implying further upside from the reported $414.87 share price. The upgrade is the clearest near-term catalyst behind the stock’s strength. Benzinga analyst upgrade report
• Positive Sentiment: Amgen announced a head-to-head Phase 3 trial for its monthly diabetes drug candidate against semaglutide. Success could strengthen the company’s position in the highly competitive GLP-1 market and provide a significant future growth opportunity, although clinical and commercial risks remain. Amgen monthly diabetes trial article
• Positive Sentiment: Cantor Fitzgerald raised its Amgen price target to $440 from $400, signaling improved expectations despite maintaining a Hold rating. Cantor Fitzgerald price target report

Amgen Trading Up 1.8%

Shares of NASDAQ:AMGN traded up $7.43 on Friday, hitting $414.87. The company had a trading volume of 2,553,004 shares, compared to its average volume of 2,753,013. The firm’s 50-day simple moving average is $412.35 and its two-hundred day simple moving average is $371.88. The firm has a market capitalization of $224.29 billion, a price-to-earnings ratio of 25.78, a P/E/G ratio of 2.98 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the previous year, the company earned $6.02 earnings per share. Amgen’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts anticipate that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. Amgen’s dividend payout ratio is 62.65%.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.